Loading...
Januvia
Antidiabetic • DPP-4 inhibitor
Inhibits dipeptidyl peptidase-4, increasing incretin levels
Drug Class
Antidiabetic
Subclass
DPP-4 inhibitor
Half-life
12.4 hours
Time for plasma concentration to decrease by 50%
Protein Binding
38%
Fraction bound to plasma proteins
Therapeutic Index
Wide
Margin between therapeutic and toxic doses